ChIP Sequencing Kit for Next Generation Sequencing
Porvair Sciences has developed a new ChIP sequencing assay kit extending the benefits of their proprietary Chromatrap solid state ChIP technology to preparation of purified Chromatin for the generation of sequencing libraries.
Chromatin immunoprecipitation (ChIP) is a technique used to detect interactions between proteins and DNA, and is based on the enrichment of DNA associated with a specific protein of interest. Combining ChIP with massively parallel sequencing (ChIP-seq) allows the accurate survey of interactions between proteins and DNA, enabling the study of epigenetic marks, which is essential for a full understanding of transcriptional regulation of genes. A precise and detailed map of protein interactions with DNA is vital for interpreting regulatory networks that underlie many biological processes and disease states, including cancer. Recent advances have identified that that the interplay between chromatin and transcription is much more dynamic and complex than initially anticipated. Previous technology using microarrays were limited by the number of unique species-specific oligonucleotide probes that could be hybridised to the chip surface. Next generation sequencing has the ability to sequence tens or hundreds of millions of short DNA fragments simultaneously, without being hybridised to an array. With single-base pair resolution, fewer artefacts, greater coverage and a larger dynamic range, ChIP-seq offers significant advantages over past technology and experiments which could only be imagined a few years ago are now becoming a reality.
Chromatrap is a new quicker, easier and more efficient way of performing ChIP-seq assays (Patent No. GB2482209). It uses discs of an inert, porous polymer to which Protein A or Protein G has been covalently attached to maximise the capture efficiency of the target chromatin/antibody complex. Chromatrap utilises the solid state technology in parallel with high throughput sequencing to deliver a precise ChIP-seq protocol from small cell numbers and chromatin concentrations. Specifically adapted for greater chromatin concentrations, Chromatrap ChIP-seq now combines the dynamic range of Chromatrap with the downstream analysis power of deep sequencing, allowing the genome wide identification of transcription factor binding sites and specific DNA associated protein modifications with no limitation in scale and resolution.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance